# Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

> **NCT04915404** · PHASE1,PHASE2 · TERMINATED · sponsor: **WPD Pharmaceuticals Sp. z o.o.** · enrollment: 5 (actual)

## Conditions studied

- Recurrent Glioblastoma Multiforme

## Interventions

- **DRUG:** Berubicin Hydrochloride

## Key facts

- **NCT ID:** NCT04915404
- **Lead sponsor:** WPD Pharmaceuticals Sp. z o.o.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-07
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915404, "Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04915404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*